IGC Pharma (IGC) Change in Accured Expenses (2010 - 2025)
IGC Pharma (IGC) posted quarterly Change in Accured Expenses of $93000.0 for Q3 2025, down 70.57% year-over-year from $316000.0 in Q3 2024, and up 115.53% quarter-over-quarter from -$599000.0 in Q2 2025.
IGC Pharma (IGC) Change in Accured Expenses (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Change in Accured Expenses for 13 consecutive years, with $93000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Accured Expenses fell 70.57% year-over-year to $93000.0; the TTM figure through Sep 2025 stood at -$1.2 million (down 344.05% YoY), while the FY2026 annual figure was -$98000.0, up 50.0% from the prior year.
- Change in Accured Expenses rose to $93000.0 in Q3 2025 per IGC's latest filing, from -$599000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $484000.0 in Q1 2023 and bottomed at -$599000.0 in Q2 2025.
- Historically, Change in Accured Expenses has averaged -$3714.3 across 4 years, with a median of $59500.0 in 2021.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses surged 236.17% — and 2025, when it sank 496.69%.
- IGC Pharma's Change in Accured Expenses stood at -$30000.0 in 2021, then tumbled by 793.33% to -$268000.0 in 2023, then rose by 19.4% to -$216000.0 in 2024, then surged by 143.06% to $93000.0 in 2025.
- Business Quant data shows IGC's Change in Accured Expenses at $93000.0 in Q3 2025, -$599000.0 in Q2 2025, and -$447000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 93,000.00 |
| Sep 30, 2025 | 93,000.00 |
| Jun 30, 2025 | -599,000.00 |
| Jun 30, 2025 | -599,000.00 |
| Mar 31, 2025 | -447,000.00 |
| Mar 31, 2025 | -447,000.00 |
| Dec 31, 2024 | -216,000.00 |
| Dec 31, 2024 | -216,000.00 |
| Sep 30, 2024 | 316,000.00 |
| Sep 30, 2024 | 316,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | -268,000.00 |
| Dec 31, 2023 | -268,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Jun 30, 2023 | 91,000.00 |